Dated: August 17, 2011.

Leslie Kux.

Acting Assistant Commissioner for Policy.
[FR Doc. 2011–21487 Filed 8–22–11; 8:45 am]
BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

2011 Technology Transfer Summit North America Conference

AGENCY: National Institutes of Health, Public Health Service, HHS. **ACTION:** Notice of Conference.

SUMMARY: The NIH Office of Technology Transfer extends invitations to attend the 2011 Technology Transfer Summit North America Conference.

DATES: October 3-4, 2011.

ADDRESSES: NIH campus, 9000 Rockville Pike, Bethesda MD, NIH Clinical Center (Building 10), Masur Auditorium.

SUPPLEMENTARY INFORMATION: The NIH campus in Bethesda, MD will be the site for the 2011 Tech Transfer Summit North America (TTSNA), the leading early-stage biotech partnering, licensing, venture and innovation platform, cohosted and co-sponsored by the NIH Office of Technology Transfer, TTS Ltd. and regional host partners such as BIO Maryland.

TTSNA is one of a series of summits held within the Global Tech Transfer Initiative and is designed specifically to put innovators, early-stage SMEs and technology managers from leading universities and research institutes together with biotech & pharma licensing & business development executives, VCs, serial entrepreneurs, and leading IP specialists for interactive sessions relating to partnering, licensing & business development.

Conference speakers for the 2011 include:

- —Kathy Hudson, Deputy Director, National Institutes of Health (NIH)
- —James C. Greenwood, President & CEO, BIO
- —Shiv Krishnan, Director, Scouting & Partnering, Sanofi, USA
- —Sanjeev Munshi, Director, Licensing and External Research, Merck & Co
- —David Kaslow, Head of Vaccines Project & Pipeline Leadership, Merck & Co
- —Ed Mascioli, Head of Orphan & Genetic Diseases Research Unit, Pfizer
- —Arthur Tzianabos, Vice President of Research, HGT Division, Shire
- —Steve Groft, Director, Office of Rare Diseases Research, NIH

- —Phil Ross, Managing Director, Healthcare, JPMorgan
- Maarten deJong, Managing Director, Barclays Capital
- —Andrew Robertson, Chief Policy Officer, BIO Ventures for Global Health
- Orin Herskowitz, Executive Director & Vice President, Intellectual Property Technology Transfer, Columbia Technology Ventures
- —Erik Lium, Assistant Vice Chancellor of Research, UCSF
- Brian Kelly, Director, Technology,
 Enterprise & Commercialisation, Weill
 Cornell Medical College
- —Daniel Perez, Partner, Bay City Capital
- —Hubert Birner, Partner, TVM Capital
- —Glen Steinbach, COO, Johns Hopkins Technology Transfer
- —Markus Goebel, Managing Director, Novartis Venture Fund

The Summit will strive to induce interactive debate, deliberation and discussion, networking and business over the 2-day period with the leaders in the sector. The Summit conference will be further enhanced by the TTS Initiative Business Social Network, an online business-networking platform powered by JuJaMa. The Network is a communication tool for business that will allow the posting of profiles and technology offers; the searching of other participants by category, by technology or licensing offer; and the setting up of meetings prior to, during and after the Summit. Total participation numbers for this conference will be strictly limited to ensure the ideal environment for real discussion and business.

FOR FURTHER INFORMATION CONTACT:

More details about the conference including registration information and the conference agenda can be found by contacting Tech Transfer Summit North America (http://

www.techtransfersummit.com/ northamerica2011). Attendees may also enter the Partner Code "NIH11" to register with a 10% reduction. For information about sign language interpretation or accommodation for disabilities, please contact Sharon Fields at telephone 301–594–7700 or fieldssh@od.nih.gov.

Dated: August 16, 2011.

Steven M. Ferguson,

Deputy Director, Licensing & Entrepreneurship, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2011–21514 Filed 8–22–11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Targeting Resistance in Select Gram-Negative Pathogens.

Date: September 22–23, 2011. Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: Hilton Silver Spring, 8727 Colesville Road, Chesapeake Room, Silver Spring, MD 20910.

Contact Person: Nancy Lewis Ernst, PhD, Scientific Review Official, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–7383, nancy.ernst@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 17, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–21512 Filed 8–22–11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Partnerships for Biodefense (R01)

Date: September 13, 2011.

Time: 12 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call)

Contact Person: Frank S. De Silva, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–594–1009, fdesilva@niaid.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Partnerships for Biodefense (R01)

Date: September 14, 2011.

Time: 12 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call)

Contact Person: Frank S. De Silva, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–594–1009, fdesilva@niaid.nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Investigator Initiated Program Project Application.

Date: September 19–20, 2011.

Time: 1 p.m. to 6 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6700B Rockledge Drive, Bethesda, MD 20817.

Contact Person: Maja Maric, PhD, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, DHHS/NIH/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892, 301–451– 2634, maja.maric@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: August 17, 2011.

Jennifer S. Spaeth,

Director. Office of Federal Advisory Committee Policy.

[FR Doc. 2011–21511 Filed 8–22–11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; The Effect of Supervised Practice Driving on Driving Performance Among Newly Licensed Teen Drivers.

Date: September 15, 2011.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call)

Contact Person: Sathasiva B. Kandasamy, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of, Child Health and Human Development, NIH 6100 Executive Blvd., Room 5b01, Bethesda, MD 20892, 301–435–6680, skandasa@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: August 17, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–21510 Filed 8–22–11; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the NIH Advisory Board for Clinical Research.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended to discuss personnel matters, the disclosure of which would constitute a clearly unwarranted invasion of privacy.

Name of Committee: NIH Advisory Board for Clinical Research

Date: October 3, 2011

Open: 10 a.m. to 1:15 p.m.

Agenda: To discuss intramural clinical research operational and funding issues.

Place: National Institutes of Health, Building 10, 10 Center Drive, CRC Medical Board Room 4–2551, Bethesda, MD 20892.

Closed: 1:15 p.m. to 2 p.m.

Agenda: To discuss personnel matters. Place: National Institutes of Health, Building 10, 10 Center Drive, CRC Medical Board Room 4–2551, Bethesda, MD 20892.

Contact Person: Maureen E Gormley, Executive Secretary, Mark O. Hatfield Clinical Research Center, National Institutes of Health, Building 10, Room 6–2551, Bethesda, MD 20892, (301) 496–2897.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit

Dated: August 17, 2011.

Jennifer S. Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2011–21509 Filed 8–22–11; 8:45 am]

BILLING CODE 4140-01-P